

## Press Release

Zug, 3 April 2012

### **HBM BioVentures publishes preliminary results for the fourth quarter and the full financial year 2011/12**

During the last quarter of the financial year ending 31 March 2012 the net asset value per share (NAV) increased by CHF 3.60 to CHF 59.60 (+6.4%). As a consequence HBM BioVentures anticipates a reduced consolidated loss for the full financial year 2011/12 in the region of CHF 25 million compared to a loss of CHF 57.4 million for the 9-month period ending 31 December 2011. For the previous financial year HBM BioVentures recorded a loss of CHF 56.4 million and the NAV stood at CHF 61.15 at the end of March 2011.

These figures are preliminary results, based on the current status of the year-end closing process. The final NAV and result for the 2011/12 financial year will be published on 3 May 2012 after the annual financial statements have been audited. The Annual Report will be published at the end of May 2012.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures, tel.: +41 41 768 11 08, [andreas.wicki@hbmbioventures.com](mailto:andreas.wicki@hbmbioventures.com)

#### **Information on HBM BioVentures Ltd**

HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM BioVentures an interesting alternative to investments in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

**HBM BioVentures**

## Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

**HBM BioVentures Ltd**

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)